The following is a summary of “Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients,” published in the December 2024 issue of Gastroenterology by Barros et al.
Researchers conducted a retrospective study to assess the diagnostic value of anti-CdtB and anti-vinculin antibodies in people with inflammatory bowel disease (IBD) who have persistent gastrointestinal symptoms.
They enrolled people with more than 3 bowel movements per day and were undergoing colonoscopies. Blood samples were collected during colonoscopy to evaluate serum levels of anti-CdtB and anti-vinculin antibodies.
The results showed that the mean optical density for anti-CdtB was 1.2 ± 0.65 in the active IBD group (n=44), 1.27 ± 0.64 in the quiescent IBD and chronic diarrhea IBD- irritable bowel syndrome (IBS) group (n=25), 1.49 ± 0.47 in the predominant-diarrhea IBS group (n=45), and 1.6 ± 0.68 in the control group (n=46), with a P-value of 0.012. For anti-vinculin, the optical densities were 1.34 ± 0.78 in the active IBD group, 1.46 ± 0.92 in the quiescent IBD and chronic diarrhea IBD-IBS group, 1.31 ± 0.79 in the predominant-diarrhea IBS group, and 1.41 ± 0.86 in the control group, with a P-value of 0.875. Using a cut-off of 1.56 for anti-CdtB, positivity was 22.7% (n=10) in active IBD, 34.6% (n=9) in quiescent IBD and chronic diarrhea IBD-IBS, 43.2% (n=19) in IBS, and 45.7% (n=21) in controls (P=0.106). For anti-vinculin, using a cut-off of 1.6, positivity was 40.9% (n=18) in active IBD, 42.3% (n=11) in quiescent IBD and chronic diarrhea IBD-IBS, 34.1% (n=15) in IBS, and 47.8% (n=22) in controls (P=0.622).
They concluded that anti-CdtB and anti-vinculin antibodies were ineffective in diagnosing IBD-IBS or distinguishing IBS-D from HCs.
Source: bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-024-03509-z
